An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04307381 |
Recruitment Status :
Active, not recruiting
First Posted : March 13, 2020
Last Update Posted : February 7, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hereditary Angioedema | Drug: Donidalorsen | Phase 2 |
This is an open-label extension study of donidalorsen in up to 24 participants with HAE. The length of participation in the study is approximately 68 weeks, which includes an up to 4-week qualification period, a 52-week treatment period, and a 12-week post-treatment period. Following the Week 53 treatment period visit, participants will receive donidalorsen in an extended treatment period for up to an additional 156 weeks. Participants taking part in the extended treatment period will enter the 12-week post-treatment period after completion of, or early termination from, the extended treatment period.
This study was extended to allow participants to receive donidalorsen for an additional 156 weeks following the initial 53-week treatment period.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 20 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-Label Extension Study of ISIS 721744 in Patients With Hereditary Angioedema |
Actual Study Start Date : | April 1, 2020 |
Estimated Primary Completion Date : | April 2025 |
Estimated Study Completion Date : | April 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Donidalorsen
Participants will be administered donidalorsen SC for up to 53 weeks. Participants will also be administered donidalorsen in the extended treatment period for an additional 156 weeks, up to week 209.
|
Drug: Donidalorsen
Donidalorsen administered SC
Other Names:
|
- Percentage of Participants with at Least One Treatment-emergent Adverse Event (TEAE), Graded by Severity [ Time Frame: Up to Week 221 ]
- The Time-normalized HAE Attacks (per Month) by Treatment [ Time Frame: Up to Week 221 ]
- Plasma Prekallikrein (PKK) Levels [ Time Frame: Up to Week 221 ]
- Consumption of On-demand Medications [ Time Frame: Up to Week 221 ]
- Angioedema Quality of Life (AE-QoL) Questionnaire Score [ Time Frame: Up to Week 221 ]The AE-QoL was developed to measure health-related quality of life (HRQoL) impairment in participants with recurrent angioedema. The AE-QoL is a self-administered questionnaire that can be completed in less than 5 minutes. It comprises 17 items across 4 domains: functioning, fatigue/mood, fears/shame, and food. Responses use a 5-point Likert scale ranging from 'never' to 'very often.' Global and domain scores range from 0 to 100, with higher scores indicating greater impairment
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Satisfactory completion of ISIS 721744-CS2 (index study) through Week 17 with an acceptable safety and tolerability profile, per Sponsor and Investigator judgement
- Able and willing to participate in a 64-week study
- Females must be non-pregnant, non-lactating and either surgically sterile or post-menopausal
- Males must be surgically sterile or abstinent* or if engaged in sexual relations with a female of child-bearing potential, participant is utilizing an acceptable contraceptive method
- Participants must have access to, and the ability to use, ≥ 1 acute medication(s) (e.g., plasma-derived or recombinant C1- inhibitor (C1-INH) concentrate or a bradykinin-2 [BK-2] antagonist) to treat angioedema attacks
Exclusion Criteria:
1. Have any new condition or worsening of an existing condition or change or anticipated change in medication, which in the opinion of the Investigator would make the participant unsuitable for enrollment, or could interfere with the participant participating in or completing the study
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04307381
United States, Arizona | |
Ionis Investigative Site | |
Scottsdale, Arizona, United States, 85251 | |
United States, California | |
Ionis Investigative Site | |
Santa Monica, California, United States, 90404 | |
United States, Minnesota | |
Ionis Investigative Site | |
Plymouth, Minnesota, United States, 55446 | |
United States, Ohio | |
Ionis Investigative Site | |
Cincinnati, Ohio, United States, 45231 | |
United States, Pennsylvania | |
Ionis Investigative Site | |
Hershey, Pennsylvania, United States, 17033 | |
United States, Texas | |
Ionis Investigative Site | |
Dallas, Texas, United States, 75231 | |
Netherlands | |
Ionis Investigative Site | |
Amsterdam, Netherlands, 1105 AZ |
Responsible Party: | Ionis Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT04307381 |
Other Study ID Numbers: |
ISIS 721744-CS3 2020-000197-14 ( EudraCT Number ) |
First Posted: | March 13, 2020 Key Record Dates |
Last Update Posted: | February 7, 2024 |
Last Verified: | February 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
Hereditary Angioedema HAE |
Angioedema Angioedemas, Hereditary Vascular Diseases Cardiovascular Diseases Urticaria Skin Diseases, Vascular Skin Diseases |
Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Hereditary Complement Deficiency Diseases Primary Immunodeficiency Diseases Genetic Diseases, Inborn Immunologic Deficiency Syndromes |